Kriya, a fully integrated company pioneering novel technologies and therapeutics in gene therapy, completed the acquisition of Warden Bio, a developer of novel gene therapies designed for glycogen storage disorders. Financial terms were not disclosed. “We are incredibly enthusiastic about the compelling research that has led to the development of Warden Bio’s pioneering gene therapies for GSDs. This acquisition and the establishment of our Rare Disease Division align with our commitment to accelerating the advancement of best-in-class gene therapies. Kriya’s technology and manufacturing platforms uniquely position our company to drive meaningful progress to address a group of diseases in desperate need of new and better treatments,” Shankar Ramaswamy, Kriya Co-Founder and Chief Executive Officer.